Drugs Made in America Acquisition (DMAAU) Stock Price, News & Analysis

Company Overview

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.

Key Stats

• Today's Range: $10.16 to $10.16
• 50-Day Range: $10.06 to $10.20
• 52-Week Range: $10.00 to $10.82
• Volume: 277 shs
• Average Volume: 77,698 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DMAAU Stock Analysis - Frequently Asked Questions

How have DMAAU shares performed this year?

Drugs Made in America Acquisition's stock was trading at $10.00 at the beginning of the year. Since then, DMAAU stock has increased by 1.6% and is now trading at $10.16.
View the best growth stocks for 2025 here.

When did Drugs Made in America Acquisition IPO?

Drugs Made in America Acquisition (DMAAU) raised $200 million in an IPO on Tuesday, January 28th 2025. The company issued 20,000,000 shares at a price of $10.00 per share. Clear Street served as the underwriter for the IPO.

When did the company's quiet period expire?

Drugs Made in America Acquisition's quiet period expired on Monday, March 10th. Drugs Made in America Acquisition had issued 20,000,000 shares in its IPO on January 28th. The total size of the offering was $200,000,000 based on an initial share price of $10.00. During the company's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Drugs Made in America Acquisition?

Shares of DMAAU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:DMAAU
• CIK: 2028614
• Web: N/A
• Phone: (954) 870-3104
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A